Correlation of Activated Clotting Time and Activated Partial Thromboplastin Time to Plasma Heparin Concentration
- 1 August 1999
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 19 (8) , 922-931
- https://doi.org/10.1592/phco.19.11.922.31573
Abstract
Study Objective. To determine the correlation between activated clotting time (ACT) or activated partial thromboplastin time (aPTT) and plasma heparin concentration. Design. Two‐phase prospective study. Setting. University‐affiliated community hospital. Patients. Thirty patients receiving continuous‐infusion intravenous heparin. Interventions. Measurement of ACT, aPTT and plasma heparin concentrations. Measurements and Main Results. Linear and log linear correlations were determined between clotting time tests and heparin concentrations. Linear correlations yielded r values of 0.58 for ACT (p=0.008) and 0.89 for aPTT (p=0.0001). Log linear correlations yielded r values of 0.60 for ACT (p=0.005) and 0.88 for aPTT (p=0.0001). A decision analysis was performed to determine possible consequences of dosage adjustments based on either test in relationship to the decision based on plasma heparin concentration. The decision analysis based on ACT disagreed with corresponding decisions based on plasma heparin concentration in 15 of 30 patients; 13 disagreements may have increased the risk of bleeding, and the other 2 may have increased the risk of thrombosis. Decisions based on aPTT disagreed with corresponding decisions based on plasma heparin concentration in 13 of 30 patients; 2 disagreements may have increased the risk of bleeding, and the other 11 may have increased the risk of thrombosis. Conclusion. There are significant statistical linear and log linear correlations between both clotting time tests and plasma heparin concentrations, with aPTT showing stronger correlation than ACT. However, decisions regarding heparin therapy based on ACT may increase a patient's risk of bleeding, whereas decisions based on aPTT may increase the risk of thrombus progression or rethrombosis.Keywords
This publication has 24 references indexed in Scilit:
- Response of kaolin ACT to heparin: Evaluation with an automated assay and higher heparin dosesThe Annals of Thoracic Surgery, 1996
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 1995
- Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and SafetyChest, 1995
- Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin timeCatheterization and Cardiovascular Diagnosis, 1994
- Establishing a Therapeutic Range for Heparin TherapyAnnals of Internal Medicine, 1993
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986
- Heparin therapy for thromboembolic disorders. A prospective evaluation of 134 cases monitored by the activated coagulation timeJAMA, 1983
- Lack of Correlation Between Activated Clotting Time and Plasma Heparin During Cardiopulmonary BypassAnnals of Surgery, 1981
- Statistical Correlation and Heparin Sensitivity of Activated Partial Thromboplastin Time, Whole Blood Coagulation Time, and an Automated Coagulation TimeAmerican Journal of Clinical Pathology, 1973
- Serum-Induced ThrombosisCirculation, 1959